Imaging has the potential to dramatically increase the efficiency of lead candidate selection by providing earlier and more highly predictive data, compared with traditional methods. Imaging is also well suited for facilitating translation between preclinical testing and clinical evaluation of drugs. Furthermore, imaging methods are more easily applied than traditional methods in the newer, more realistic models of human disease that are becoming increasingly prevalent.

Charles River has an in vivo imaging facility with high-field MRI, PET/CT and SPECT/CT scanners for radionuclide-based imaging applications. All platforms are applicable for longitudinal studies with multiple imaging endpoints to study phenotype progression and treatment efficacy, biodistribution or tissue activity changes.

Request imaging information »

We've answered some frequently asked questions about imaging below. You can also learn more by watching our nuclear imaging webinar.

Can imaging be performed along with other tests in the same animal?

Yes. The advantage of nuclear imaging is that it can be combined with other studies such as behavioral studies, histology and anatomical image MRIs.

When biochemical analyses (e.g., IHC, Western blotting, microscopy) are performed on postmortem samples from animals injected with radioactive tracers, are these analyses conducted in a lab certified for isotope work or are the samples stored in quarantine until the isotope decays?
Can the distribution of supramolecular structures (e.g., liposomes, nanoparticles) be imaged?
Does Charles River offer receptor occupancy studies and how do these studies compare with PET imaging data?
For the 18F-TSPO ligand, is autoradiography preferred over PET imaging for the EAE, cuprizone and LPS models?
Does Charles River have access to a cyclotron? Can custom radiolabeling of molecules with F-18, radioiodines and radiometals be performed?
Does Charles River have the ability to measure in vivo bioluminescence using reporter mice?
What is a typical sample size for efficacy studies using PET/SPECT imaging?
Has Charles River used imaging to quantify amyloid plaques in models of Alzheimer’s disease?
Do you have the hardware and skills for multi-spectral optoacoustic tomography for use with fluorescent probes?

I need to...